Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse

• Published in: International journal of clinical oncology Vol. 26; no. 11; pp. 2142 - 2150
• Main Authors: Yasui, Hiroshi, Kobayashi, Masayuki, Sato, Kota, Kondoh, Kanya, Ishida, Tadao, Kaito, Yuta, Tamura, Hideto, Handa, Hiroshi, Tsukune, Yutaka, Sasaki, Makoto, Komatsu, Norio, Tanaka, Norina, Tanaka, Junji, Kizaki, Masahiro, Kawamata, Toyotaka, Makiyama, Junya, Yokoyama, Kazuaki, Imoto, Seiya, Tojo, Arinobu, Imai, Yoichi
• Format: Journal Article
• Language: English
• Published: Singapore Springer Singapore 01.11.2021; Springer Nature B.V
• Subjects: Biomarkers; Cancer Research; Deoxyribonucleic acid; DNA; Light chains; Malignancy; Medicine; Medicine & Public Health; Multiple myeloma; Mutation; Next-generation sequencing; Oncology; Original Article; Patients; Peripheral blood; Surgical Oncology; Liquid biopsy; Biomarker; Relapse; Next generation sequencing; Multiple Myeloma
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-021-01991-z

Background Multiple myeloma (MM) is an incurable hematological malignancy. Despite the introduction of several novel drugs, most patients relapse. Biomarkers to identify the early signs of relapse will make it possible to adjust the therapeutic strategy before the disease worsens. Although understanding genetic changes is important for the treatment of MM, currently known biomarkers of relapse, including serum free-light chains and monoclonal paraproteins, are not associated with genetic changes. Methods We therefore performed a multicenter study to examine the usefulness of circulating cell-free DNA (cfDNA) present in the peripheral blood (PB) plasma of patients as a biomarker for MM relapse. Results We identified several driver mutations by combined analysis of next-generation sequencing and existing databases of candidate oncogenes. Furthermore, relapse was detected more sensitively by monitoring the circulating cfDNA with these driver mutations than by conventional serum free-light chain examination. Conclusion These results suggest the potential utility of cfDNA in the PB plasma of patients as a relevant early biomarker for MM relapse.